TB 500 Dosage: What the Research Reported

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

Is there an established TB 500 dosage?

Short version: no. The honest starting point is that there is no legitimate TB 500 dosage to give you — and understanding why is far more useful than any figure copied off a forum. TB-500 has never been through the human dose-finding trials that produce a real prescribing range. A 2026 scoping review of thymosin beta-4 and TB-500 in tissue healing and musculoskeletal repair concluded that the evidence is largely preclinical with limited human data, and that there is no completed, published human randomized trial of the injected TB-500 fragment for injury, muscle, or athletic use. There is no FDA-approved product, so there is no approved strength, no approved schedule, and no regulated manufacturer standing behind what is in the vial.

That is why this article does not walk you through reconstitution, syringe units, or an injection schedule. Those steps imply a safe, known quantity exists. It doesn't. TB-500 is a synthetic, N-acetylated fragment corresponding to residues 17-23 of the full thymosin beta-4 protein — the actin-binding domain, per the sourced description of TB-500 — sold as a "research chemical," not as a characterized human drug. What the literature offers instead of a dose is a set of conventions borrowed from animal work: figures that describe what some people have done, not what has been shown safe or effective in humans.

Why is self-dosing gray-market TB-500 dangerous?

This is the part that matters most, so it comes before any numbers. When you buy TB-500 from a research-chemical vendor and inject it, you have no reliable way to know what is actually in the vial — and the data on that channel are alarming.

The clearest evidence comes from a peer-reviewed 2024 analysis in JMIR that tested injectable peptide products sold online by sellers without a prescription — the same gray-market channel that markets TB-500. It found bacterial endotoxin in 100% of samples, measured active-ingredient purity of just 7.7% to 14.37% against a claimed 99%, and reported that roughly 59-64% of products failed basic visual-quality criteria. Add the possibility of the wrong sequence entirely or heavy-metal contamination, and the picture is of a product category you cannot dose safely because you cannot trust the contents.

People often wave this away with a certificate showing "99% purity." Here is the catch, and it is the core reason a tested, licensed channel matters: a purity test checks identity, not sterility or endotoxin. It tells you the molecule roughly matches the label. It does not tell you the vial is free of the bacterial endotoxin that the JMIR analysis found in every sample. A vial can be pure on paper and still make you sick when injected.

Two more risks sit on top of contamination. First, TB-500 is prohibited in sport. Thymosin beta-4 and its derivatives, including TB-500, are on the WADA Prohibited List under Section S2 and are banned at all times, in and out of competition; the anti-doping lab BSCG notes it has been listed since 2011, and athletes have received four-year bans for it. For any tested competitor, a single positive can be career-ending. Second, injected peptides carry an immunogenicity risk — whether repeated injection provokes an immune response — that the FDA specifically flagged as unassessed. So "how much, how often, for how long" has no evidence-based answer.

What TB 500 dosage did protocols in the literature report?

With all of that context in place, here is what protocols circulating online and in the literature have reported — presented as convention, not instruction. It is worth stating plainly that these figures are not doses in the medical sense; they are community-derived conventions and animal-equivalent extrapolations, and the 2026 scoping review confirms no published human trial of the fragment establishes any of them.

The most commonly cited pattern is a two-phase structure: a loading phase of roughly 2 to 2.5 mg twice weekly for about 4 to 6 weeks, followed by a maintenance phase around 2 to 2.5 mg once weekly or every one to two weeks, with reported cycles running about 6 to 12 weeks. These figures trace back to mechanism work on the parent protein — thymosin beta-4 sequesters actin and has been described as driving cell migration and VEGF-linked angiogenesis in the 2021 Frontiers in Endocrinology review — not to any human trial of the injected fragment.

Reported figure	What it actually is
~2-2.5 mg twice weekly "loading" for ~4-6 weeks	A community convention drawn from animal-equivalent scaling and online protocols — not an FDA-established dose or a trial-validated range.
~2-2.5 mg weekly or every 1-2 weeks "maintenance"	A usage habit, not a dose confirmed by any human study of the TB-500 fragment.
~6-12 week cycles	A convention, not a safety-tested duration; the longest human thymosin beta-4 trials ran only ~180 days and were topical or ophthalmic, not injected TB-500.
"99% purity" certificate	An identity check only — it does not measure sterility or endotoxin, which was present in 100% of JMIR-tested samples.

Every row in that table is a caveat. There is no validated human dose to hand anyone, which is precisely why no responsible source should be giving you an injection schedule. If you want the head-to-head with the peptide TB-500 is most often stacked with, we cover that separately in BPC-157 and TB-500 combined rather than restating it here.

How long is TB-500 considered safe to take?

There is no established human safety window for injected TB-500, and that gap is easy to underestimate. The real human trial data belong to the full thymosin beta-4 protein used as a topical or ophthalmic drug (RGN-259), not to the self-injected fragment — and those trials are short. Human dermal wound-healing work reached only Phase 2, and the ophthalmic program's registered Phase 3 trials ran on the order of weeks to about 180 days. There is no chronic, high-dose human safety study of the injected TB-500 fragment at all.

The one recurring theoretical concern worth naming: TB-500's proposed mechanism is pro-angiogenic — it is described as promoting the growth of new blood vessels. That is a mechanism-based caution for anyone with active cancer, because new blood-vessel growth can, in theory, feed an existing tumor. This is a theoretical, mechanism-level concern rather than a documented harm from TB-500, but it is exactly the kind of question a real dose-finding safety program would have to answer before any human dose could be called safe — and no such program exists for the injected fragment.

What is the FDA status of TB-500?

TB-500 is not FDA-approved and is not on the 503A Bulks List, which means there is no legal pathway to compound or sell it for human use today. As a thymosin beta-4 fragment it has been treated as a 503A "Category 2" substance — one that may present a significant safety risk — with the FDA noting that both its free-base and acetate forms are not well physically or chemically characterized.

At the FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 (docket FDA-2025-N-6895, announced in the Federal Register), TB-500 was among the peptides reviewed, and FDA staff proposed that these peptides not be added to the compounding list — citing that they are poorly characterized, with little human efficacy evidence and insufficient safety data including unassessed immunogenicity. Two points of precision matter: that committee is advisory and non-binding, and any final rule would require formal notice-and-comment rulemaking. So the accurate framing is "FDA staff proposed not to list it," not "the FDA banned it." Either way, the practical reality is the same — there is no legitimate, tested channel to obtain a properly dosed TB-500 product today.

Where Nouri fits — and why sourcing peptides safely matters

A dose only means something inside a legitimate supply chain: a characterized product, a known concentration, sterility and endotoxin testing, a prescriber, and a manufacturer accountable for the vial. None of that exists for peptides sold by research-chemical vendors, which is exactly what the JMIR contamination data reflect. That is why chasing a "correct" TB-500 dosage is a dead end — the number was never the problem, the channel is.

Nouri does not sell TB-500 or any peptide, and there is no approved product to offer. What we can do is be straight about where the science and the regulations actually stand — and let you be first to know if and when licensed, tested peptide options ever become available through a legitimate, prescribed channel. If that matters to you, you can join the Nouri peptide waitlist. It is not a preorder and implies no availability date; it is simply a way to be notified if the regulatory picture changes.

To go deeper, start with our pillar explainer, what TB-500 is and what the science shows. For the biology of the parent molecule and its real human clinical program, read thymosin beta-4 explained. And for an honest, benefit-by-benefit look at the evidence, see what the research is and isn't showing about TB-500 benefits.

Frequently asked questions

Is there an FDA-approved TB 500 dosage? No. TB-500 is not FDA-approved and is not on the 503A Bulks List, so there is no approved product and no FDA-established dose. The figures circulated online come from community protocols and animal-equivalent scaling, not from a validated human dosing trial. A 2026 scoping review found no completed published human randomized trial of the fragment for injury or athletic use.

What TB 500 dosage did protocols in the literature report? Protocols circulating online report a loading phase of roughly 2 to 2.5 mg twice weekly for about 4 to 6 weeks, then a maintenance dose around 2 to 2.5 mg once weekly or every one to two weeks, with cycles of about 6 to 12 weeks. These are conventions and animal-equivalent extrapolations, not FDA-established or RCT-validated human doses.

Why is self-dosing gray-market TB-500 dangerous? Because you cannot verify the contents. A 2024 JMIR analysis found endotoxin in 100% of tested products and purity of 7.7-14.37% against a claimed 99%, with a majority failing basic visual criteria. TB-500 is also prohibited by WADA at all times, and injected peptides carry an immunogenicity risk the FDA says it could not rule out.

Does a "99% pure" label make TB-500 safe to inject? No. A purity certificate tests identity, not sterility or endotoxin. A vial can read 99% pure and still carry the bacterial endotoxin that the 2024 JMIR analysis found in every sample, or contain the wrong sequence. Purity on paper is not the same as safe to inject.

Is TB-500 banned in sport? Yes. Thymosin beta-4 and its derivatives, including TB-500, are on the WADA Prohibited List under Section S2 and are prohibited at all times, in and out of competition, and have been since 2011. Athletes have received four-year bans, so for a tested competitor a single positive can be career-ending.

How long is TB-500 considered safe to take? There is no established human safety window for injected TB-500. The longest human thymosin beta-4 trials ran only about 180 days and were topical or ophthalmic, not injected TB-500. Its pro-angiogenic mechanism is also a theoretical caution for anyone with active cancer.

Sources & data

Primary and secondary sources cited above:

• Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription — JMIR, 2024 (endotoxin in 100% of samples; purity 7.7-14.37% vs 99% claimed). The study analyzed unprescribed injectable peptide products of the type the gray market also sells as TB-500.
• Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review — Applied Sciences, 2026 (evidence largely preclinical; no completed human RCT of the injected fragment).
• Progress on the Function and Application of Thymosin beta-4 — Frontiers in Endocrinology, 2021 (actin sequestration, VEGF-driven angiogenesis, cell migration; catalog of human Phase I/II trials).
• Thymosin beta-4 Promotes Dermal Healing — Vitamins and Hormones, 2016 (human Phase 2 dermal wound-healing signals; parent protein, not injected TB-500).
• 0.1% RGN-259 (Thymosin beta-4) Ophthalmic Solution for Neurotrophic Keratopathy: A Phase III Clinical Trial — International Journal of Molecular Sciences, 2023 (registered human Phase 3 data for a Tβ4 eye drop, not injected TB-500).
• TB-500 — encyclopedic entry (identity: N-acetylated Tβ4 residues 17-23 fragment; prescription-only in AU/NZ; WADA-prohibited).
• TB-500: Status, Risks, and Bans in Sport and Military — BSCG (accredited anti-doping lab; WADA Section S2 status, four-year bans).
• Pharmacy Compounding Advisory Committee Notice of Meeting — Federal Register (July 23-24, 2026 review; docket FDA-2025-N-6895).

This article is educational and is not medical advice. TB-500 is not FDA-approved, has no validated human dose, and has no legal compounding or sales pathway at this time. Do not attempt to source or self-inject peptides from unregulated vendors.

Want to be notified if licensed, tested peptide options ever become available? Join the Nouri peptide waitlist — no preorder, no obligation, just first notice if the regulatory picture changes.